Navigation Links
Apex Bioventures Acquisition Corp. Sets Date for Special Meeting of Stockholders to Approve Dissolution
Date:5/7/2009

HILLSBOROUGH, Calif., May 7 /PRNewswire-FirstCall/ -- Apex Bioventures Acquisition Corporation (NYSE Amex: PEX) ("Apex") announced today that a special meeting of stockholders will be held at 10:00 a.m. local time on Tuesday, June 2, 2009, at the offices of Mintz Levin Cohn Ferris Glovsky & Popeo, P.C., located at 666 Third Avenue, New York, NY 10017.

At the special meeting, Apex's stockholders will be asked to consider and vote on a plan of liquidation and dissolution of Apex. Stockholders of record as of the close of business on May 15, 2009 will be entitled to vote at the special meeting.

Additional Information and Where to Find It

This press release is not a proxy statement or a solicitation of proxies from Apex's stockholders. Any solicitation of proxies will be made only by the definitive proxy statement of Apex that will be mailed to all stockholders. Stockholders of Apex and other interested persons are advised to read Apex's preliminary proxy statement and definitive proxy statement, when available, in connection with Apex's solicitation of proxies for the special meeting because these proxy statements will contain important information about Apex and the proposed dissolution. Apex's preliminary proxy statement is available from the SEC's website at http://www.sec.gov/. The definitive proxy statement will be mailed to stockholders of record as of the close of business on May 15, 2009.

Apex and its directors and officers may be deemed to be participants in the solicitation of Apex's stockholders in connection with the proposed liquidation and other matters with respect to which the company's stockholders will be asked to vote pursuant to the proxy statement. Information regarding the names, affiliations and interests of such individuals is contained in Apex's prospectus dated June 6, 2007 and the preliminary proxy statement and will be contained in the definitive proxy statement when it becomes available.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements are based on current expectations and are subject to numerous risks, assumptions and uncertainties, many of which change over time and are beyond Apex's control. Actual results may differ materially from those anticipated in any forward-looking statement and you should not place any undue reliance on such forward-looking statements. More detailed information about Apex and risk factors that may affect the realization of forward-looking statements, including forward-looking statements in this press release, is set forth in Apex's filings with the Securities and Exchange Commission. Apex urges investors and security holders to read those documents free of charge at the Commission's web site at http://www.sec.gov. Interested parties may also obtain these documents free of charge from Apex. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, Apex undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.


'/>"/>
SOURCE Apex Bioventures Acquisition Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
2. Apex Bioventures Announces Trust Investment Details
3. Rcadia Medical Imaging Closes $3.3 Million Investment Led by BioVentures Investors
4. Apex Bioventures Acquisition Corp. To Seek Stockholder Approval To Liquidate and Dissolve
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
7. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
8. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
11. Siemens Extends Tender Offer for Acquisition of Dade Behring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology: